Home  |   Archive  |   Online Submission  |   News & Events  |   Subscribe  |   APFA  |   Society  |   Contact Us  |   中文版
Search   
 
Journal

-Ahead of print
-Authors' Accepted
    Manuscripts
new!
-Current Issue
-Archive
-Acknowledgments
-Special Issues
-Browse by Category

Manuscript Submission

-Online Submission
-Online Review
-Instruction for Authors
-Instruction for Reviewers
-English Corner new!

About AJA

-About AJA
-Editorial Board
-Contact Us
-News

Resources & Services

-Advertisement
-Subscription
-Email alert
-Proceedings
-Reprints

Download area

-Copyright licence
-EndNote style file
-Manuscript word template
-Guidance for AJA figures
    preparation (in English)

-Guidance for AJA figures
    preparation (in Chinese)

-Proof-reading for the
    authors

-AJA Club (in English)
-AJA Club (in Chinese)

 
中文摘要

《亚洲男性学杂志》 2013; 15 (4): 483-486

中国男性(初始PSA小于4ng ml-1)的PSA变化及其影响因素的纵向研究

Ming Liu, Jian-Ye Wang, Hong-Xue Su, Gang Wan, Ling Zhu and Xiao-Ming Wang (中国)

评估血清前列腺特异抗原(PSA)的长期变化以及初始PSA对其变化的影响。回顾性分析北京医院体检中心2007年3月至2011年11月体检资料。选择初始PSA小于4ng ml-1且连续5年每年进行PSA检查者进行研究。根据其初始PSA水平分为4组,(0–0.99, 1–1.99,2–2.99 和 3–3.99 ng ml-1),分析各组间PSA速率(PSAV)的差异。共纳入1330例男性进行研究,其平均年龄、初始PSA以及PSAV分别为58.17±14.63 (24–91)岁, 1.18±0.79 (0–4)ng ml-1以及0.04±0.25 (21.34–2.02)ng ml-1 每年。皮尔森相关性分析显示初始PSA水平与PSAV无相关性(r=0.036, P=0.189)。初始PSA 0–0.99, 1–1.99, 2–2.99 和 3–3.99 ng ml-1组的PSAV分别为0.03±0.11, 0.07±0.32, 0.03±0.34 and -0.01±0.43 ng ml-1 每年(P=0.06)。随着初始PSA水平的升高,出现异常PSAV(﹥0.75 ng ml-1每年)的比例以及出现PSAV小于0的比例均增高。初始PSA 0–0.99, 1–1.99, 2–2.99 和 3–3.99 ng ml-1组的男性在未来4年中分别有1.88%, 6.16%, 16.30% 和57.81%的机会PSA大于4.0 ng ml-1(P<0.0001)。结论:PSAV与初始PSA水平无关,但是随着初始PSA水平升高,未来出现异常PSA或PSAV的可能性增加。

关键词:男性,前列腺癌(PCa),前列腺癌肿瘤抗原,前列腺特异性抗原(PSA),PSA速度

此摘要文献来源:
Ming Liu, Jian-Ye Wang, Hong-Xue Su, Gang Wan, Ling Zhu et al. A longitudinal study of PSA and its influential factors in a cohort of Chinese
men with initial PSA levels less than 4 ng ml-1. Asian J Androl 2013; 15: 483-6.

 
Asian Journal of Andrology CN 31-1795/R ISSN 1008-682X  Copyright © 2023  Shanghai Materia Medica, Chinese Academy of Sciences.  All rights reserved.